Log in to search using one of your social media accounts:

 

A great place to do great things: Developing game-changing technology at Abbott
Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an evaluation of 23 characteristics including financial strength, easy adaptation to change, and a research-driven environment. (Source: World Pharma News)
Source: World Pharma News - October 20, 2017 Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news

MSD Innovation Factory is looking for digital solutions for anaesthesiologists
MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons. As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value to healthcare professionals, patients and customers. (Source: World Pharma News)
Source: World Pharma News - October 20, 2017 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
The U.S. Food and Drug Administration approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL). (Source: World Pharma News)
Source: World Pharma News - October 20, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Merck brings customers closer to gene therapy product commercialization
Merck today announced that its Carlsbad, California-based manufacturing facility for the production of BioReliance® viral and gene therapy products has completed both a U.S. Food & Drug Administration (FDA) Pre-License inspection and a European Medicines Agency (EMA) Marketing Authorization Application inspection. (Source: World Pharma News)
Source: World Pharma News - October 19, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Scientists find where HIV 'hides' to evade detection by the immune system
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human body to evade detection by the immune system. The team, led by Associate Professor Sarah Palmer from the University of Sydney, developed a pioneering full-length genetic sequencing assay for HIV. (Source: World Pharma News)
Source: World Pharma News - October 19, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings. (Source: World Pharma News)
Source: World Pharma News - October 18, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Three of the most deadly cancers get critical funding for research
Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the deadliest forms of cancer: glioblastoma (brain cancer), sarcoma (bone cancer) and ovarian cancer. Three scientists have received $1.3 million in critical funding from the Alliance for Cancer Gene Therapy (ACGT), the nation's only nonprofit dedicated exclusively to cell and gene therapies for cancer. (Source: World Pharma News)
Source: World Pharma News - October 18, 2017 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

FDA accepts Bristol-Myers Squibb's application for Opdivo (nivolumab) in patients with resected high-risk advanced melanoma and grants priority review
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection. The FDA also previously granted Breakthrough Therapy Designation for this application, (Source: World Pharma News)
Source: World Pharma News - October 17, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Parallel Trade Conference 2018
6 - 7 February 2018, London, UK. SMi Group's Parallel Trade conference returns to London for its 12th year. Over the years, the European Single market has allowed for pharmaceuticals to be imported and exported freely between member states without the permission of the manufacturers. However, with the arrival of Brexit and guidelines to immanently enforce the Falsified Medicines Directive (FMD) by 2019, the market for pharmaceutical parallel trade is changing. (Source: World Pharma News)
Source: World Pharma News - October 17, 2017 Category: Pharmaceuticals Tags: Featured Events Source Type: news

AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology
AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Turnstone Biologics, a clinical-stage immuno-oncology company, have announced a research, option and license agreement whereby AbbVie obtained an exclusive option to license up to three of Turnstone's next-generation oncolytic viral immunotherapies. (Source: World Pharma News)
Source: World Pharma News - October 16, 2017 Category: Pharmaceuticals Tags: Featured AbbVie Business and Industry Source Type: news

Magic mushrooms may 'reset' the brains of depressed patients
Patients taking psilocybin to treat depression show reduced symptoms weeks after treatment following a 'reset' of their brain activity. The findings come from a study in which researchers from Imperial College London used psilocybin - the psychoactive compound that occurs naturally in magic mushrooms - to treat a small number of patients with depression in whom conventional treatment had failed. (Source: World Pharma News)
Source: World Pharma News - October 16, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

eyeforpharma Barcelona 2018
13 - 15 March 2018, Barcelona, Spain. eyeforpharma Barcelona is an annual pilgrimage for pharma's executives who want to map their future commercial success. Now it has become the place to map a different journey, that of our customers and patients. Gain their trust and serve as their guiding light towards better outcomes for all. (Source: World Pharma News)
Source: World Pharma News - October 13, 2017 Category: Pharmaceuticals Tags: Featured Conferences Events Source Type: news

Chemistry provides a new supply of a promising cancer and HIV treatment
A drug isolated from a marine pest holds promise for treating some of the world's nastiest diseases, and researchers would love to find out just how effective it is - if only they could get their hands on more. As it stands, the world's supply of the chemical is down to about half of what it was in the 1990s, and it is hard to extract in sufficient quantities from the feathery sea creatures that produce it. (Source: World Pharma News)
Source: World Pharma News - October 13, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer reviewing strategic alternatives for Consumer Healthcare business
Pfizer Inc. is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business. This announcement is part of Pfizer's continuing efforts to allocate resources and capital to best serve patients and maximize value for its shareholders. (Source: World Pharma News)
Source: World Pharma News - October 12, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

New drug hope for rare bone cancer patients
Patients with a rare bone cancer of the skull and spine - chordoma - could be helped by existing drugs, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal National Orthopaedic Hospital NHS Trust. In the largest genomics study of chordoma to date, published today in Nature Communications, scientists show that a group of chordoma patients have mutations in genes that are the target of existing drugs, known as PI3K inhibitors. (Source: World Pharma News)
Source: World Pharma News - October 12, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - October 11, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Allergy drug improves function in patients with chronic injury from multiple sclerosis
In a remarkably rapid translation of laboratory research findings into a treatment with the potential to benefit patients, UC San Francisco scientists have successfully completed a Phase II clinical trial showing that an FDA-approved antihistamine restores nervous system function in patients with chronic multiple sclerosis (MS). (Source: World Pharma News)
Source: World Pharma News - October 11, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Indian government needs to do more to tackle rising sale of unapproved antibiotics
In India, the sale of antibiotics requiring the tightest control and regulation is rising the fastest, according to an analysis by researchers at Queen Mary University of London (QMUL) and Newcastle University. The correspondence published in The Lancet Global Health highlights serious hurdles for controlling antimicrobial resistance in the country. (Source: World Pharma News)
Source: World Pharma News - October 10, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Safe to treat dementia patients with clot-busting drugs
Stroke patients with dementia treated with intravenous thrombolysis using powerful clot-busting drugs are at no higher risk of brain haemorrhage or death than other patients receiving the same treatment, a study from Karolinska Institutet published in the journal Neurology reports. (Source: World Pharma News)
Source: World Pharma News - October 10, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Social Media in the Pharmaceutical Industry
22 - 23 January 2018, London, UK. Social media is the perfect channel for pharmaceutical companies to educate, market, listen and connect with customers, patients and physicians. How the pharmaceutical industry utilize social media is particularly complex as regulators such as the FDA have not yet written the rules about how pharmaceuticals can engage with potential customers and patients. (Source: World Pharma News)
Source: World Pharma News - October 9, 2017 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams
Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings. The solution fundamentally changes the way these meetings are organised and conducted. (Source: World Pharma News)
Source: World Pharma News - October 9, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

FDA awards 15 grants for clinical trials to stimulate product development for rare diseases
The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country. (Source: World Pharma News)
Source: World Pharma News - October 6, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA awards six grants for natural history studies in rare diseases
The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to inform medical product development by better understanding how specific rare diseases progress over time. (Source: World Pharma News)
Source: World Pharma News - October 6, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Pfizer launches novel programs to put important support services at the fingertips of cancer patients
Pfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer Oncology medicines that offers dedicated social workers called 'Care Champions' to help navigate the complexities that accompany treatment, such as identifying resources to help find emotional support, and workplace transition, transportation and financial assistance. (Source: World Pharma News)
Source: World Pharma News - October 5, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

A need for bananas? Dietary potassium regulates calcification of arteries
Bananas and avocados - foods that are rich in potassium - may help protect against pathogenic vascular calcification, also known as hardening of the arteries. University of Alabama at Birmingham researchers have shown, for the first time, that reduced dietary potassium promotes elevated aortic stiffness in a mouse model, as compared with normal-potassium-fed mice. (Source: World Pharma News)
Source: World Pharma News - October 5, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Caregivers wish liver cancer received greater public awareness in the U.S., new survey reveals
Bristol-Myers Squibb Company (NYSE:BMY), in collaboration with Blue Faery: The Adrienne Wilson Liver Cancer Association, a leading liver cancer patient advocacy organization, today announced the findings from a new survey exploring the experiences of caregivers of people living with early or advanced stage liver cancer in the U.S. (Source: World Pharma News)
Source: World Pharma News - October 4, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

The Nobel Prize in Chemistry 2017 - Cool microscope technology revolutionises biochemistry
We may soon have detailed images of life's complex machineries in atomic resolution. The Nobel Prize in Chemistry 2017 is awarded to Jacques Dubochet, Joachim Frank and Richard Henderson for the development of cryo-electron microscopy, which both simplifies and improves the imaging of biomolecules. This method has moved biochemistry into a new era. (Source: World Pharma News)
Source: World Pharma News - October 4, 2017 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Amgen and CytomX Therapeutics announce strategic collaboration in immuno-oncology
Amgen (NASDAQ:AMGN) and CytomX Therapeutics, Inc., (NASDAQ:CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX ProbodyTM T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types. (Source: World Pharma News)
Source: World Pharma News - October 3, 2017 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Printed meds could reinvent pharmacies, drug research
A technology that can print pure, ultra-precise doses of drugs onto a wide variety of surfaces could one day enable on-site printing of custom-dosed medications at pharmacies, hospitals and other locations. The technique, which was developed at the University of Michigan, can print multiple medications into a single dose on a dissolvable strip, microneedle patch or other dosing device. (Source: World Pharma News)
Source: World Pharma News - October 2, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Abbott acquisition of Alere set to close on Tuesday, October 3, 2017
Abbott (NYSE: ABT) announced today it intends to close the acquisition of Alere, Inc., on Tuesday, Oct. 3, 2017. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction establishes Abbott as the global leader in point of care testing - the fastest-growing segment of the $50 billion in vitro diagnostics market - and further strengthens the company's diagnostics presence. (Source: World Pharma News)
Source: World Pharma News - October 2, 2017 Category: Pharmaceuticals Tags: Featured Abbott Business and Industry Source Type: news

A new approach to cancer drug discovery
Scientists at The Scripps Research Institute (TSRI) have developed and demonstrated a promising new strategy for the discovery of novel anti-cancer therapies. The TSRI scientists, collaborating with scientists at Pfizer, used their new approach to find small-molecule inhibitors of a protein that is important for the growth of non-small-cell lung cancers (NSCLCs). These cancers represent about 85 percent of lung cancers and are relatively insensitive to drug treatment. (Source: World Pharma News)
Source: World Pharma News - September 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among people with type 2 diabetes
To mark World Heart Day today, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigating the level of CVD awareness and knowledge among people living with type 2 diabetes. The global survey - Taking Diabetes to Heart - is available in multiple languages until March 2018, and people with type 2 diabetes are encouraged to participate. (Source: World Pharma News)
Source: World Pharma News - September 29, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

FDA improves access to reports of adverse drug reactions
The U.S. Food and Drug Administration today launched a new user-friendly search tool that improves access to data on adverse events associated with drug and biologic products through the FDA's Adverse Event Reporting System (FAERS). The tool is designed to make it easier for consumers, providers, and researchers to access this information. (Source: World Pharma News)
Source: World Pharma News - September 28, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered "undruggable." (Source: World Pharma News)
Source: World Pharma News - September 28, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Amgen and Simcere announce strategic collaboration to co-develop and commercialize biosimilars in China
Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group have announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology. (Source: World Pharma News)
Source: World Pharma News - September 27, 2017 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Up to $20,000 available to the digital health company that solves one of the challenges proposed by MSD
MSD is looking for innovators to solve 7 health-related challenges aiming to support physician education or patient disease management. The 3 digital solutions with the most outstanding value will receive up to $20,000 each to be launched in a local market. MSD will also work side by side with the winning solvers to facilitate the roll-out of their solution. (Source: World Pharma News)
Source: World Pharma News - September 27, 2017 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Daiichi Sankyo announces TaNeDS Global 2018 collaborative drug discovery program
Daiichi Sankyo Company, Limited today announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global 2018, a collaborative drug discovery initiative for universities and research institutes in Europe and the East Coast of the United States. (Source: World Pharma News)
Source: World Pharma News - September 26, 2017 Category: Pharmaceuticals Tags: Featured Daiichi Sankyo Business and Industry Source Type: news

FDA conducts major global operation to protect consumers from potentially dangerous prescription drugs sold online
The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, recently took action against more than 500 websites that illegally sell potentially dangerous, unapproved versions of prescription medicines, including opioids, antibiotics and injectable epinephrine products to American consumers. (Source: World Pharma News)
Source: World Pharma News - September 26, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD
AstraZeneca today announced positive top-line results of the Phase III, PINNACLE 4 trial in which Bevespi Aerosphere* (glycopyrronium and formoterol fumarate 14.4/9.6 µg) demonstrated a statistically significant improvement in lung function as measured by trough forced expiratory volume in one second (FEV1), compared to its monotherapy components (glycopyrronium 14.4 µg and formoterol fumarate 9.6 µg) and placebo, (Source: World Pharma News)
Source: World Pharma News - September 25, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Amgen Foundation pledges up to $5 million to Hurricane Maria relief efforts
Amgen (NASDAQ:AMGN) announced that the Amgen Foundation has pledged $3 million to support urgent Hurricane Maria relief efforts in Puerto Rico. The Foundation also has committed up to an additional $2 million for longer-term rebuilding efforts. Amgen is also activating its Staff Disaster Relief Fund to aid Amgen staff in Puerto Rico, including financial assistance for shelter, medical attention, clothing and other critical relief. (Source: World Pharma News)
Source: World Pharma News - September 25, 2017 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors
AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - September 22, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in lower-income countries through the Glivec International Patient Assistance Program (GIPAP), (Source: World Pharma News)
Source: World Pharma News - September 22, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Danish discovery can pave the way for more effective cholesterol medicine
More than 600,000 Danes are being treated with cholesterol lowering medicine. 98 per cent of them are treated with statins, which curb the body's own production of cholesterol so that the level of cholesterol falls. However, statins also give rise to the body forming more of a harmful protein - known as PCSK9 - which counters the effect of the statins. (Source: World Pharma News)
Source: World Pharma News - September 21, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents
With approximately EUR 417,000, the Bayer Science & Education Foundation is providing a record amount for 65 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions. (Source: World Pharma News)
Source: World Pharma News - September 21, 2017 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Pfizer goes to Court to allow competition for biologics and expand options for patients
To ensure patients and providers have access to important, lower cost biosimilar medicines, Pfizer (NYSE:PFE) has filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson & Johnson (J&J). The suit alleges that J&J's exclusionary contracts and other anticompetitive practices have denied U.S. patients access to therapeutic options and undermined the benefits of robust price competition in the innovative and growing biologics marketplace for patients. (Source: World Pharma News)
Source: World Pharma News - September 20, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

SMi presents Europe's leading 10th annual conference and exhibition: Pre-Filled Syringes Europe 2018
17 - 18 January 2018, London, UK. Join the calendar event highlight for the medical device industry at Europe's leading 10th annual conference and exhibition on Pre-Filled Syringes when it returns to Central London on 17th and 18th January 2018. Pre-Filled Syringes Europe will once again provide a perfect platform to discuss new advancements and showcase the latest innovations to keep you at the forefront of a dynamic and booming market. (Source: World Pharma News)
Source: World Pharma News - September 20, 2017 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Scientists find way to convert bad body fat into good fat
There's good fat and bad fat in our bodies. The good fat helps burn calories, while the bad fat hoards calories, contributing to weight gain and obesity. Now, new research at Washington University School of Medicine in St. Louis has identified a way to convert bad, white fat into good, brown fat, at least in mice. (Source: World Pharma News)
Source: World Pharma News - September 20, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to 'listen for the sounds of IPF'
IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.(1) Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost. However, diagnosis can be challenging.(1,2) This year for IPF World Week (16 - 24 September), Boehringer Ingelheim is raising awareness of (Source: World Pharma News)
Source: World Pharma News - September 19, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Beta blockers not needed after heart attack if other medications taken
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge the current clinical guideline that heart-attack survivors should take all three drugs - beta blockers, ACE inhibitors and statins - for the rest of their lives. (Source: World Pharma News)
Source: World Pharma News - September 19, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Johnson & Johnson announces collaboration with U.S. Department of Health and Human Services to fight influenza
Johnson & Johnson (NYSE: JNJ) announced that Janssen Research & Development LLC (Janssen) are collaborating with the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to develop a comprehensive portfolio of therapeutics and vaccines to protect communities in the event of an influenza pandemic and other infectious disease threats. (Source: World Pharma News)
Source: World Pharma News - September 18, 2017 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news